Trial · NCT03291379
Results by group107
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 107
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| To Assess the Safety and Tolerability of Treatment With BTG-002814 | BTG-002814 | participants with treatment emergent Adverse Events (AEs) | 8 | Participants | |
| To Assess the Safety and Tolerability of Treatment With BTG-002814 | BTG-002814 | participants with treatment emergent Serious Adverse Events (SAEs) | 4 | Participants | |
| Maximum Concentration (Cmax) of Vandetanib and N-desmethyl Vandetanib in Plasma Following Treatment With BTG-002814 | BTG-002814 | Vandetanib Plasma Cmax | 24.3 | Standard Deviation 13.94 | ng/mL |
| Maximum Concentration (Cmax) of Vandetanib and N-desmethyl Vandetanib in Plasma Following Treatment With BTG-002814 | BTG-002814 | N-desmethyl Plasma Cmax | 0.6 | Standard Deviation 0.82 | ng/mL |
| Concentration of Vandetanib in Resected Liver Tissue Following Treatment With BTG-002814 | BTG-002814 | Subject 01: Vandetanib concentration centre of tumour | 404000 | ng/mL | |
| Concentration of Vandetanib in Resected Liver Tissue Following Treatment With BTG-002814 | BTG-002814 | Subject 01: Vandetanib concentration middle of tumour | 394000 | ng/mL | |
| Concentration of Vandetanib in Resected Liver Tissue Following Treatment With BTG-002814 | BTG-002814 | Subject 01: Vandetanib concentration edge of tumour | 327000 | ng/mL | |
| Concentration of Vandetanib in Resected Liver Tissue Following Treatment With BTG-002814 | BTG-002814 | Subject 01: Vandetanib concentration 1cm away from tumour | 10800 | ng/mL | |
| Concentration of Vandetanib in Resected Liver Tissue Following Treatment With BTG-002814 | BTG-002814 | Subject 03: Vandetanib concentration centre of tumour | 8510 | ng/mL | |
| Concentration of Vandetanib in Resected Liver Tissue Following Treatment With BTG-002814 | BTG-002814 | Subject 03: Vandetanib concentration middle of tumour | 11000 | ng/mL | |
| Concentration of Vandetanib in Resected Liver Tissue Following Treatment With BTG-002814 | BTG-002814 | Subject 03: Vandetanib concentration edge of tumour | 18800 | ng/mL | |
| Concentration of Vandetanib in Resected Liver Tissue Following Treatment With BTG-002814 | BTG-002814 | Subject 03: Vandetanib concentration 1cm away from tumour | 9120 | ng/mL | |
| Concentration of Vandetanib in Resected Liver Tissue Following Treatment With BTG-002814 | BTG-002814 | Subject 05: Vandetanib concentration centre of tumour | 7340 | ng/mL | |
| Concentration of Vandetanib in Resected Liver Tissue Following Treatment With BTG-002814 | BTG-002814 | Subject 05: Vandetanib concentration middle of tumour | 7550 | ng/mL | |
| Concentration of Vandetanib in Resected Liver Tissue Following Treatment With BTG-002814 | BTG-002814 | Subject 05: Vandetanib concentration edge of tumour | 12500 | ng/mL | |
| Concentration of Vandetanib in Resected Liver Tissue Following Treatment With BTG-002814 | BTG-002814 | Subject 05: Vandetanib concentration 1cm away from tumour | 7090 | ng/mL | |
| Concentration of Vandetanib in Resected Liver Tissue Following Treatment With BTG-002814 | BTG-002814 | Subject 06: Vandetanib concentration centre of tumour | 160000 | ng/mL | |
| Concentration of Vandetanib in Resected Liver Tissue Following Treatment With BTG-002814 | BTG-002814 | Subject 06: Vandetanib concentration middle of tumour | 151000 | ng/mL | |
| Concentration of Vandetanib in Resected Liver Tissue Following Treatment With BTG-002814 | BTG-002814 | Subject 06: Vandetanib concentration edge of tumour | 11100 | ng/mL | |
| Concentration of Vandetanib in Resected Liver Tissue Following Treatment With BTG-002814 | BTG-002814 | Subject 06: Vandetanib concentration 1cm away from tumour | 1480 | ng/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03291379/results